- Home
- EVER vs DNTH Comparison
EVER vs DNTH Comparison
Compare EVER & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVER
- DNTH
- Stock Information
- Founded
- EVER 2008
- DNTH 2015
- Country
- EVER United States
- DNTH United States
- Employees
- EVER N/A
- DNTH N/A
- Industry
- EVER Computer Software: Programming Data Processing
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- EVER Technology
- DNTH Health Care
- Exchange
- EVER Nasdaq
- DNTH Nasdaq
- Market Cap
- EVER 735.7M
- DNTH 670.7M
- IPO Year
- EVER 2018
- DNTH N/A
- Fundamental
- Price
- EVER $21.63
- DNTH $22.29
- Analyst Decision
- EVER Strong Buy
- DNTH Strong Buy
- Analyst Count
- EVER 6
- DNTH 9
- Target Price
- EVER $31.67
- DNTH $46.43
- AVG Volume (30 Days)
- EVER 446.9K
- DNTH 245.5K
- Earning Date
- EVER 02-24-2025
- DNTH 03-20-2025
- Dividend Yield
- EVER N/A
- DNTH N/A
- EPS Growth
- EVER N/A
- DNTH N/A
- EPS
- EVER 0.38
- DNTH N/A
- Revenue
- EVER $408,440,000.00
- DNTH $5,366,000.00
- Revenue This Year
- EVER $72.34
- DNTH $100.14
- Revenue Next Year
- EVER $18.98
- DNTH N/A
- P/E Ratio
- EVER $57.53
- DNTH N/A
- Revenue Growth
- EVER 27.43
- DNTH 51.41
- 52 Week Low
- EVER $13.07
- DNTH $18.35
- 52 Week High
- EVER $28.09
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- EVER 64.61
- DNTH 49.77
- Support Level
- EVER $19.28
- DNTH $21.28
- Resistance Level
- EVER $21.41
- DNTH $23.28
- Average True Range (ATR)
- EVER 0.97
- DNTH 1.75
- MACD
- EVER 0.25
- DNTH 0.17
- Stochastic Oscillator
- EVER 98.85
- DNTH 79.92
About EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.